Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for KERX
5.82
-0.22 (-3.56%)
Real-time:   9:55AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.80 - 6.02
52 week 2.80 - 7.80
Open 6.01
Vol / Avg. 84,547.00/1.69M
Mkt cap 642.76M
P/E     -
Div/yield     -
EPS -1.56
Shares 105.96M
Beta 5.05
Inst. own 65%
Feb 23, 2017
Q4 2016 Keryx Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 15, 2016
Keryx Biopharmaceuticals Inc at Stifel Healthcare Conference
Nov 9, 2016
Q3 2016 Keryx Biopharmaceuticals Inc Earnings Release
Nov 9, 2016
Q3 2016 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
Sep 27, 2016
Keryx Biopharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference - Webcast
Sep 13, 2016
Keryx Biopharmaceuticals Inc at Morgan Stanley Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -657.98% -900.18%
Operating margin -660.03% -811.90%
EBITD margin - -807.54%
Return on average assets -87.95% -67.98%
Return on average equity -408.69% -153.53%
Employees 184 -
CDP Score - -

Address

1 Marina Park Dr
BOSTON, MA 02210-1832
United States - Map
+1-617-4663500 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.

Officers and directors

Gregory Paul Madison Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Scott A. Holmes Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Brian R. Adams Vice President, General Counsel
Age: 41
Bio & Compensation  - Reuters
Douglas M. Jermasek Vice President of Marketing and Strategy
Bio & Compensation  - Reuters
John F. Neylan Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Lauren Fischer Director
Bio & Compensation  - Reuters
John P. Butler Independent Director
Age: 51
Bio & Compensation  - Reuters
Kevin J. Cameron Independent Director
Age: 46
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven C. Gilman Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters